However, we observed selective involvement of CXCR4 in significantly modulating paclitaxel resistance in breast and colon cancers, which is actually in corollary with vast literature documenting the pro-tumorigenic role of CXCR4. This evidence concerns the gene CXCR4 and malignant colon neoplasm.